Pyrazoloacridine

N/A

Report date: 2022/08/29 20:00:24
NME

Base Information

Drug NamePyrazoloacridine
Drug Alias Name吡唑啉吖啶PD-115934PZANSC-366140
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitorsDNA topoisomerase I inhibitors
TargetsTopoisomerase IIDNA topoisomerase I
Therapy Area/IndicationsUveal melanomaSkin MelanomaCNS Embryonal Tumor +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSouth Africa +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBarbara Ann Karmanos Cancer InstituteNational Cancer InstituteThe University Of Texas MD Anderson Cancer Center +[5] 
Active IndicationsN/A
Inactive IndicationsUveal melanomaSkin MelanomaCNS Embryonal Tumor +[10] 

Other Information

ATC CodeN/A
Related LinksN/A